Therefore, treatment with a combination of TKIs and PARP1 inhibitors could be a potential approach to overcome TKI resistance and improve prognosis, but the exact involvement of PARP1 in the autophagy of NSCLC cells is still poorly understood. The gene discussed is PARP1; the disease is non-small cell lung carcinoma.